BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it has been awarded an additional $136,245 from the U.S. Food and Drug Administration’s (FDA’s) Office of Orphan Products Development for continued development of its Tß4 drug candidate (RGN-137) for treatment of patients with Epidermolysis Bullosa (EB), a rare and debilitating skin blistering disorder.
